Τρίτη 2 Μαΐου 2017

Durvalumab receives accelerated FDA approval for metastatic urothelial carcinoma after platinum

The U.S. Food and Drug Administration has granted accelerated approval to durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pSTvV4
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις